Edgewise Therapeutics Inc. Common Stock vs Levi Strauss & Co. — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.06 (market cap $3.94B), while Levi Strauss & Co. trades at $19.6 (market cap $7.47B). The key difference: Levi Strauss & Co. is the larger of the two by market cap, and Levi Strauss & Co. pays a 3.29% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Levi Strauss & Co. for 71 Days on average.
| EWTX | LEVI | |
|---|---|---|
Market Cap | $3.94B | $7.47B |
Volume | 810,104 | 6,427,839 |
Sector | Health | Consumer Cyclical |
52-Week High | $48.35 | $25.53 |
52-Week Low | $14.89 | $17.92 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $3.48B | $9.02B |
Dividend Yield | — | 3.29% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Levi Strauss (LEVI) trades at $19.57, up 1.72% with strong fundamentals including a 12.82 P/E ratio and 25.76% ROE. The stock shows bearish technical signals but has consistently beaten earnings expectations for four consecutive quarters. Recent news highlights the company's successful '90s fashion revival and appointment of a new CFO, while analyst consensus remains strongly bullish with a $29 price target representing 48% upside potential.
The investment case balances attractive valuation against technical weakness. Strong profitability metrics and consistent earnings beats support upside, but bearish technical indicators and execution risks in the competitive apparel sector warrant caution. The 78.95% buy rating from analysts suggests significant institutional confidence in Levi's growth trajectory despite near-term market sentiment concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →